Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10996.145 | 1.0692 | 1.2461 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10996.145 | 1.0041 | 1.0142 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12192.145 | 1.0112 | 1.0539 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12192.145 | 1.0071 | 1.0341 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12192.145 | 1.0051 | 1.0243 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12192.145 | 1.0827 | 1.4194 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12192.145 | 1.0129 | 1.0622 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12192.145 | 1.0384 | 1.1889 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12192.145 | 0.9712 | 0.8649 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12192.145 | 1.0707 | 1.3557 | 0.4175 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12192.145 | 1.0321 | 1.1572 | 0.4175 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10577.145 | 1.0290 | 1.0600 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10577.145 | 0.9485 | 0.8937 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10577.145 | 1.0270 | 1.0559 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10577.145 | 0.9897 | 0.9788 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10577.145 | 0.9780 | 0.9545 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10577.145 | 0.9510 | 0.8988 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10577.145 | 1.0192 | 1.0398 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10577.145 | 0.8950 | 0.7833 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10577.145 | 0.7604 | 0.5069 | 0.9676 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10937.145 | 0.9734 | 0.9559 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10937.145 | 1.0239 | 1.0394 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10937.145 | 0.9892 | 0.9822 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10937.145 | 1.0550 | 1.0905 | 1.2098 | |
| HCC3153 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10937.145 | 0.9705 | 0.9512 | 1.2098 |